TNFRSF8 and neoplasm: Although CD30 remains an excellent target for CAR-T therapy of HL, various obstacles should be overcome to clinically improve their efficacy, such as the persistence of CAR-T cells, trafficking to tumors, and increased tumor cytotoxicity (Ramos et al., 2017; Hong et al., 2018; Grover and Savoldo, 2019; Hombach et al., 2019).